Benign prostatic hyperplasia (BPH) is a condition in which the prostate gland becomes enlarged due to abnormal cell growth. This enlargement is not related to cancer and does not increase the risk of developing prostate cancer. However, it is possible to have an enlarged prostate at the same time that there are areas in the prostate gland that contain cancer cells. The symptoms of BPH and prostate cancer may be similar, so it is important to talk to your healthcare provider if you have any urinary problems.
Prostate cancer can also cause symptoms unrelated to BPH. The prostate-specific antigen (PSA) blood test and the digital rectal exam (DRE) are two tests used to detect prostate cancer. It is important to note that BPH will not turn into cancer. However, some evidence suggests that people who take certain medications may have a higher risk of developing a more serious form of prostate cancer (high-grade prostate cancer).
Prostate stones can also form around or inside the prostate gland due to obstructions caused by chronic inflammation or BPH. Prostate cancer occurs in the prostate gland, which is located just below the bladder in men and surrounds the upper part of the tube that drains urine from the bladder (urethra). Many prostate cancers grow slowly and are limited to the prostate gland, where they may not cause serious damage. However, if prostate cancer spreads to other parts of the body, such as the bones, the bone cancer cells are actually prostate cancer cells.
When patients are told that their symptoms are likely due to an enlarged prostate due to BPH, which is benign, they often continue to feel anxious about whether this condition may increase their chances of developing cancer. A family history of prostate cancer or certain types of breast cancer increases the chance of being diagnosed with prostate cancer. Abnormal results from any of the tests may be due to benign prostatic enlargement (BPH) or infection, rather than cancer. A prostate biopsy is usually done with an ultrasound probe to view the prostate and guide the biopsy.
This method has been approved by the FDA for destroying prostate tissue, but not for treating prostate cancer.